stockrowArrowhead Pharmaceuticals, Inc.
ARWR Healthcare Biotechnology
Arrowhead Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $829.4 million, up 23,258.2% from fiscal 2024.
- Revenue
- +171.0%
- EPS
- −7.94%
- Free cash flow
- −15.4%
- Total debt
- +259.5%
Quarter to June 2026, against a year earlier
Follow ARWR
Alert me
Arrowhead Pharmaceuticals, Inc. (ARWR) Free cash flow margin
Arrowhead Pharmaceuticals, Inc.'s free cash flow margin over the twelve months to 30 June 2026 was −11.2%, down 30.1 percentage points from fiscal 2025 (18.9%). Over the past ten years it has ranged from −43,138.2% (fiscal 2016) to 106.8% (fiscal 2021); the current reading is higher than 82% of that period. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | 18.9% | 17,037.21 |
| FY2024 | −17,018.3% | (16,880.96) |
| FY2023 | −137.3% | (59.67) |
| FY2022 | −77.7% | (184.51) |
| FY2021 | 106.8% | 229.30 |
| FY2020 | −122.5% | (217.86) |
| FY2019 | 95.4% | 396.75 |
| FY2018 | −301.4% | (199.92) |
| FY2017 | −101.4% | 43,036.73 |
| FY2016 | −43,138.2% | (25,421.48) |
Against its own ten years
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| KRYS Krystal Biotech, Inc. compare | 66.0% |
| PTGX Protagonist Therapeutics, Inc. compare | 46.3% |
| CORT Corcept Therapeutics Incorporated compare | 20.2% |
| CAI Caris Life Sciences,�Inc. compare | 8.00% |
| SYRE Spyre Therapeutics, Inc. compare | 0.00% |
| ARWR Arrowhead Pharmaceuticals, Inc. | −11.2% |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −11.8% |
| TWST Twist Bioscience Corporation compare | −22.2% |
| CYTK Cytokinetics, Incorporated compare | −519.5% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on ARWR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement